Connect with us

Hi, what are you looking for?

Saturday, Jul 2, 2022
Mugglehead Magazine
Alternative investment news based in Vancouver, B.C.

Business

Khiron to acquire EU-GMP-certified German pharmaceuticals manufacturer

The transaction is set to close on or before the end of July

Khiron to acquire EU-GMP-certified German pharmaceuticals manufacturer
Photo via Khiron

Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC) is set to acquire a certified German pharmaceutical manufacturer and expand its presence in Europe.

On Tuesday, the Toronto-headquartered company with primary operations in Colombia announced it entered into an agreement to acquire Pharmadrug GmbH from its parent company PharmaDrug Inc. (CSE:PHRX) (OTC:LMLLF).

Pharmadrug is an EU-GMP and EU-GDP certified decades-old manufacturer and wholesaler of medicinal products and active pharmaceutical ingredients.

Under the agreement, Khiron will acquire all the shares of Pharmadrug for a promissory note issued at closing and 5.5 million Khiron shares at a price of $0.16.

The promissory note will total $1.1 million, will carry no interests and will be repayable one year from the date of issue in cash or in additional shares.

The transaction is set to close on or before the end of July but is still subject to customary closing conditions such as the approval of the TSX Venture Exchange.

Khiron stock went up by 6.06 per cent on Tuesday to $0.18 on the Canadian Ventures Exchange.

Read more: Khiron ups revenue by 60% to $12.8 million year-over-year

Read more: 92% of patients report improvements in chronic pain after using cannabis oil: Khiron study

President of Khiron Europe Franziska Katterbach said the acquisition will have a direct positive impact on the company’s revenues and higher gross margins.

“The long-established German company will be instrumental in expanding Khiron’s product portfolio with new dosage formats and bringing Khiron’s full-spectrum extracts to Germany and the United Kingdom to grow the patient base,” Katterbach said.

“Our team in Europe is excited to join forces with new colleagues from Pharmadrug GmbH, with their valuable expertise in the German pharmaceutical market.”

 

Follow Mugglehead on Twitter

Like Mugglehead on Facebook

Click to comment

Leave a Reply

Your email address will not be published.

You May Also Like

Health and Safety

Science doesn't know yet, but one psychedelic researcher is chasing clues to see if it can

Canada

As more medium-to-small producers came into play this year, great weed started hitting legal shelves at fairer prices

Culture

Punishments for possession include caning and the death penalty. Despite a global trend of reform, The Fine City remains staunch in its anti-drug stance

Analysis

While legal weed businesses decry enforcement of their accounts, the platform says it's keeping its all-ages community safe